(Q39737049)

14 September 2017

title

Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide (English)

1 reference

14 September 2017

1 reference

James T Milnes

1

1 reference

14 September 2017

Harry J Witchel

2

1 reference

14 September 2017

Joanne L Leaney

3

1 reference

14 September 2017

Derek J Leishman

4

1 reference

14 September 2017

Jules C Hancox

5

1 reference

14 September 2017

publication date

19 February 2010

1 reference

Journal of Pharmacological and Toxicological Methods

14 September 2017

published in

1 reference

14 September 2017

volume

61

1 reference

14 September 2017

issue

2

1 reference

14 September 2017

page(s)

178-191

1 reference

Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Time course and voltage dependence of expressed HERG current compared with native "rapid" delayed rectifier K current during the cardiac ventricular action potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

The hERG potassium channel and hERG screening for drug-induced torsades de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Endogenous Kv channels in human embryonic kidney (HEK-293) cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Molecular determinants of HERG channel block.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Molecular determinants of hERG channel block by terfenadine and cisapride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Cardiac ion channel effects of tolterodine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

I Kr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

A method for making rapid changes of superfusate whilst maintaining temperature at 37 degrees C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Intracellular K+ is required for the inactivation-induced high-affinity binding of cisapride to HERG channels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Effects of premature stimulation on HERG K(+) channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

The N588K-HERG K+ channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 degrees C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

hERG K+ channel blockade by the antipsychotic drug thioridazine: An obligatory role for the S6 helix residue F656.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

A structural basis for drug-induced long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Rb+ flux through hERG channels affects the potency of channel blocking drugs: correlation with data obtained using a high-throughput Rb+ efflux assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Lidoflazine is a high affinity blocker of the HERG K(+)channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

State dependent dissociation of HERG channel inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a Novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Temperature dependence of human ether-a-go-go-related gene K+ currents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Dofetilide block involves interactions with open and inactivated states of HERG channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Drug induced QT prolongation and torsades de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.02.007

10.1016/J.VASCN.2010.02.007

7 January 2021

Identifiers

DOI

1 reference

14 September 2017

1 reference